Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer

By afschroeder • June 25, 2025

LeVee A, Peluso E, Lechner MG, Ruel N, Mortimer J, Kang I, Tsai K. Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer. Oncologist. 2025 Jun 4;30(6):oyaf134. doi: 10.1093/oncolo/oyaf134. PMID: 40549044.

Tags: breast cancer, Denosumab, Endocrinology, immune-related adverse events, immunotherapy, pembrolizumab, Publications

Do measures of general versus pregnancy-related anxiety have distinct maternal-fetal-placental biology?

Duberstein ZT, Murphy H, Wu Q, Meng Y, Wang C, Smith R, Salafia C, Chowdhury SF, Barrett E, Scheible K, Qiu X, O'Connor TG. Do[...]

Type 2 Diabetes Risk Perception and Health Behaviors Among Women with History of Gestational Diabetes Mellitus: A Retrospective Analysis

Malone A, Tibbe TD, Turk N, Duru OK, Wisk LE, Mangione C, Page J, Thomas SC, Vu A, Madievsky R, Chon J, Cheng F, Liu[...]

Allodynia and Dysesthesia Associated With Semaglutide and Tirzepatide

Ahern S. Allodynia and Dysesthesia Associated With Semaglutide and Tirzepatide. Cureus. 2025 Oct 8;17(10):e94126. doi: 10.7759/cureus.94126. PMID: 41210042; PMCID: PMC12594042.